文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

乳腺癌的生物学和分子异质性与其癌症干细胞含量相关。

Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

机构信息

IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.

出版信息

Cell. 2010 Jan 8;140(1):62-73. doi: 10.1016/j.cell.2009.12.007.


DOI:10.1016/j.cell.2009.12.007
PMID:20074520
Abstract

Pathways that govern stem cell (SC) function are often subverted in cancer. Here, we report the isolation to near purity of human normal mammary SCs (hNMSCs), from cultured mammospheres, on the basis of their ability to retain the lipophilic dye PKH26 as a consequence of their quiescent nature. PKH26-positive cells possess all the characteristics of hNMSCs. The transcriptional profile of PKH26-positive cells (hNMSC signature) was able to predict biological and molecular features of breast cancers. By using markers of the hNMSC signature, we prospectively isolated SCs from the normal gland and from breast tumors. Poorly differentiated (G3) cancers displayed higher content of prospectively isolated cancer SCs (CSCs) than did well-differentiated (G1) cancers. By comparing G3 and G1 tumors in xenotransplantation experiments, we directly demonstrated that G3s are enriched in CSCs. Our data support the notion that the heterogeneous phenotypical and molecular traits of human breast cancers are a function of their CSC content.

摘要

调控干细胞(SC)功能的途径在癌症中经常被颠覆。在这里,我们报告了基于其静止特性而保留亲脂性染料 PKH26 的能力,从培养的乳腺球体中分离出接近纯的人正常乳腺 SC(hNMSC)。PKH26 阳性细胞具有 hNMSC 的所有特征。PKH26 阳性细胞的转录谱(hNMSC 特征)能够预测乳腺癌的生物学和分子特征。通过使用 hNMSC 特征的标记物,我们从正常腺体和乳腺肿瘤中前瞻性地分离了 SC。分化不良(G3)的癌症比分化良好(G1)的癌症显示出更高含量的前瞻性分离的癌症 SC(CSC)。通过在异种移植实验中比较 G3 和 G1 肿瘤,我们直接证明 G3 富含 CSC。我们的数据支持这样的观点,即人类乳腺癌异质性表型和分子特征是其 CSC 含量的功能。

相似文献

[1]
Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.

Cell. 2010-1-8

[2]
Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.

Arch Dermatol Res. 2012-6-28

[3]
Culture and characterization of mammary cancer stem cells in mammospheres.

Methods Mol Biol. 2015

[4]
ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

Cancer Res. 2013-10-18

[5]
Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature.

Br J Cancer. 2013-6-25

[6]
Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.

Stem Cells. 2011-1

[7]
High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.

Oncotarget. 2015-10-13

[8]
Identification of Cancer Stem Cells in Esophageal Adenocarcinoma.

Methods Mol Biol. 2018

[9]
Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking.

Proteomics. 2019-9-8

[10]
[Stem cells and epithelial cancers: the example of breast cancer].

Ann Pathol. 2008-11

引用本文的文献

[1]
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments.

Signal Transduct Target Ther. 2025-8-25

[2]
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.

bioRxiv. 2025-6-5

[3]
The CRL7 Complex Controls the Mammary Stem Cell Compartment through Regulation of NUMB Levels.

Adv Sci (Weinh). 2025-7

[4]
Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping.

Breast Cancer Res. 2025-5-21

[5]
Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.

Cancers (Basel). 2025-5-1

[6]
Diversity of ER-positive and HER2-negative breast cancer stem cells attained using selective culture techniques.

Sci Rep. 2025-3-10

[7]
Distinct clinicopathological features and treatment differences in breast cancer patients of young age.

Sci Rep. 2025-2-15

[8]
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

J Exp Clin Cancer Res. 2025-1-20

[9]
DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer.

Cancer Res. 2025-3-3

[10]
Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment.

Discov Oncol. 2024-12-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索